Published in FASEB J on May 01, 2001
Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol (2010) 3.44
Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest (2004) 3.09
Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J Clin Invest (2006) 2.13
Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res (2001) 1.88
Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med (Berl) (2008) 1.86
IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J Cell Biol (2008) 1.76
TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J (2007) 1.60
Revolutionizing medicine in the 21st century through systems approaches. Biotechnol J (2012) 1.60
TNF-alpha regulates myogenesis and muscle regeneration by activating p38 MAPK. Am J Physiol Cell Physiol (2006) 1.55
Dlk1 is necessary for proper skeletal muscle development and regeneration. PLoS One (2010) 1.28
Neutrophils contribute to muscle injury and impair its resolution after lengthening contractions in mice. J Physiol (2004) 1.28
TNF inhibits Notch-1 in skeletal muscle cells by Ezh2 and DNA methylation mediated repression: implications in duchenne muscular dystrophy. PLoS One (2010) 1.28
Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease. Gastroenterology (2010) 1.26
miR-29 targets Akt3 to reduce proliferation and facilitate differentiation of myoblasts in skeletal muscle development. Cell Death Dis (2013) 1.26
Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol Cell Biol (2004) 1.24
Reactive oxygen species in skeletal muscle signaling. J Signal Transduct (2011) 1.23
Genomic profiling of messenger RNAs and microRNAs reveals potential mechanisms of TWEAK-induced skeletal muscle wasting in mice. PLoS One (2010) 1.22
Cancer cachexia--pathophysiology and management. J Gastroenterol (2013) 1.20
Inflammation and cachexia in chronic kidney disease. Pediatr Nephrol (2010) 1.20
Genetic ablation of TWEAK augments regeneration and post-injury growth of skeletal muscle in mice. Am J Pathol (2010) 1.13
A systems biology approach identifies molecular networks defining skeletal muscle abnormalities in chronic obstructive pulmonary disease. PLoS Comput Biol (2011) 1.13
Glutathione depletion impairs myogenic differentiation of murine skeletal muscle C2C12 cells through sustained NF-kappaB activation. Am J Pathol (2004) 1.10
Malnutrition and ageing. Postgrad Med J (2006) 1.08
Wasting mechanisms in muscular dystrophy. Int J Biochem Cell Biol (2013) 1.07
TACE release of TNF-alpha mediates mechanotransduction-induced activation of p38 MAPK and myogenesis. J Cell Sci (2007) 1.07
Effects of low-level laser therapy on expression of TNF-α and TGF-β in skeletal muscle during the repair process. Lasers Med Sci (2010) 1.07
The omega-3 fatty acid, eicosapentaenoic acid (EPA), prevents the damaging effects of tumour necrosis factor (TNF)-alpha during murine skeletal muscle cell differentiation. Lipids Health Dis (2008) 1.05
Hypothalamic mechanisms in cachexia. Physiol Behav (2010) 1.04
Rethinking regenerative medicine: a macrophage-centered approach. Front Immunol (2014) 1.03
Insulin-like growth factor I-mediated skeletal muscle hypertrophy is characterized by increased mTOR-p70S6K signaling without increased Akt phosphorylation. J Investig Med (2005) 1.00
Segregation of myoblast fusion and muscle-specific gene expression by distinct ligand-dependent inactivation of GSK-3β. Cell Mol Life Sci (2010) 0.99
Tumor necrosis factor-α regulates distinct molecular pathways and gene networks in cultured skeletal muscle cells. PLoS One (2010) 0.99
RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol (2007) 0.96
The TWEAK-Fn14 system: breaking the silence of cytokine-induced skeletal muscle wasting. Curr Mol Med (2012) 0.96
Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis (2005) 0.95
NF-κB negatively impacts the myogenic potential of muscle-derived stem cells. Mol Ther (2011) 0.95
Pro-inflammatory mediation of myoblast proliferation. PLoS One (2014) 0.94
The effects of obesity on skeletal muscle regeneration. Front Physiol (2013) 0.93
Pregnancy-associated plasma protein-A regulates myoblast proliferation and differentiation through an insulin-like growth factor-dependent mechanism. J Biol Chem (2005) 0.92
Downhill running in rats: influence on neutrophils, macrophages, and MyoD+ cells in skeletal muscle. Eur J Appl Physiol (2003) 0.91
METTL21C is a potential pleiotropic gene for osteoporosis and sarcopenia acting through the modulation of the NF-κB signaling pathway. J Bone Miner Res (2014) 0.91
Effect of photobiomodulation on expression of IL-1β in skeletal muscle following acute injury. Lasers Med Sci (2012) 0.90
Longevity and skeletal muscle mass: the role of IGF signalling, the sirtuins, dietary restriction and protein intake. Aging Cell (2015) 0.90
Proteomic analysis of altered protein expression in skeletal muscle of rats in a hypermetabolic state induced by burn sepsis. Biochem J (2006) 0.87
RNAi screen reveals potentially novel roles of cytokines in myoblast differentiation. PLoS One (2013) 0.87
Skeletal Muscle Loss is Associated with TNF Mediated Insufficient Skeletal Myogenic Activation After Burn. Shock (2015) 0.84
Large-scale isolation of human skeletal muscle satellite cells from post-mortem tissue and development of quantitative assays to evaluate modulators of myogenesis. J Cachexia Sarcopenia Muscle (2013) 0.83
RhoA mediates defective stem cell function and heterotopic ossification in dystrophic muscle of mice. FASEB J (2013) 0.83
Co-activation of nuclear factor-κB and myocardin/serum response factor conveys the hypertrophy signal of high insulin levels in cardiac myoblasts. J Biol Chem (2014) 0.83
Alternative splicing factor ASF/SF2 is down regulated in inflamed muscle. J Clin Pathol (2006) 0.83
Distinct roles of TRAF6 at early and late stages of muscle pathology in the mdx model of Duchenne muscular dystrophy. Hum Mol Genet (2013) 0.83
Stem cell transplantation for muscular dystrophy: the challenge of immune response. Biomed Res Int (2014) 0.83
Dietary Flaxseed Mitigates Impaired Skeletal Muscle Regeneration: in Vivo, in Vitro and in Silico Studies. Int J Med Sci (2016) 0.83
TNF-α and IGF1 modify the microRNA signature in skeletal muscle cell differentiation. Cell Commun Signal (2015) 0.81
Muscle progenitor cell regenerative capacity in the torn rotator cuff. J Orthop Res (2015) 0.81
Epigenetic drugs in the treatment of skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care (2008) 0.80
Inhibition of mammalian muscle differentiation by regeneration blastema extract of Sternopygus macrurus. Dev Dyn (2008) 0.80
IL-1α reversibly inhibits skeletal muscle ryanodine receptor. a novel mechanism for critical illness myopathy? Am J Respir Cell Mol Biol (2014) 0.80
Association of tumor necrosis factor-alpha-863C/A gene polymorphism with chronic obstructive pulmonary disease. Lung (2010) 0.79
Regulation of myogenic activation of p38 MAPK by TACE-mediated TNFα release. Front Cell Dev Biol (2014) 0.78
Local and systemic pathogenesis and consequences of regimen-induced inflammatory responses in patients with head and neck cancer receiving chemoradiation. Mediators Inflamm (2014) 0.78
Downhill exercise-induced changes in gene expression related with macrophage polarization and myogenic cells in the triceps long head of rats. Inflammation (2015) 0.78
Chromatin signaling in muscle stem cells: interpreting the regenerative microenvironment. Front Aging Neurosci (2015) 0.78
The influence of IL-10 and TNFα on chondrogenesis of human mesenchymal stromal cells in three-dimensional cultures. Int J Mol Sci (2014) 0.78
Genetic deletion of TNFR2 augments inflammatory response and blunts satellite-cell-mediated recovery response in a hind limb ischemia model. FASEB J (2014) 0.77
Boron nitride nanotube-mediated stimulation of cell co-culture on micro-engineered hydrogels. PLoS One (2013) 0.77
The quasi-parallel lives of satellite cells and atrophying muscle. Front Aging Neurosci (2015) 0.77
Short-Wave Diathermy Pretreatment and Inflammatory Myokine Response After High-Intensity Eccentric Exercise. J Athl Train (2015) 0.76
Pharmacological inhibition of GSK-3 in a guinea pig model of LPS-induced pulmonary inflammation: II. Effects on skeletal muscle atrophy. Respir Res (2013) 0.76
CCAAT/enhancer binding protein beta protects muscle satellite cells from apoptosis after injury and in cancer cachexia. Cell Death Dis (2016) 0.76
The Janus-Faced Role of Antioxidants in Cancer Cachexia: New Insights on the Established Concepts. Oxid Med Cell Longev (2016) 0.75
Notch Signaling Mediates Skeletal Muscle Atrophy in Cancer Cachexia Caused by Osteosarcoma. Sarcoma (2016) 0.75
Tumor Necrosis Factor Alpha and Insulin-Like Growth Factor 1 Induced Modifications of the Gene Expression Kinetics of Differentiating Skeletal Muscle Cells. PLoS One (2015) 0.75
SIRT3, a mitochondrial NAD⁺-dependent deacetylase, is involved in the regulation of myoblast differentiation. PLoS One (2014) 0.75
A novel in vitro model of sarcopenia using BubR1 hypomorphic C2C12 myoblasts. Cytotechnology (2015) 0.75
Gene expression is differentially regulated in skeletal muscle and circulating immune cells in response to an acute bout of high-load strength exercise. Genes Nutr (2017) 0.75
Potential Role of Omega-3 Fatty Acids on the Myogenic Program of Satellite Cells. Nutr Metab Insights (2016) 0.75
Impaired regeneration: A role for the muscle microenvironment in cancer cachexia. Semin Cell Dev Biol (2015) 0.75
Lipopolysaccharide inhibits myogenic differentiation of C2C12 myoblasts through the Toll-like receptor 4-nuclear factor-κB signaling pathway and myoblast-derived tumor necrosis factor-α. PLoS One (2017) 0.75
Inflammation and Oxidation Biomarkers in Patients with Cystic Fibrosis: The Influence of Azithromycin. Eurasian J Med (2017) 0.75
The Ror1 receptor tyrosine kinase plays a critical role in regulating satellite cell proliferation during regeneration of injured muscle. J Biol Chem (2017) 0.75
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
Recommendations on the use of exercise testing in clinical practice. Eur Respir J (2007) 3.15
Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial. Thorax (2009) 3.12
Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 3.09
Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax (1996) 2.33
Impairment of quality of life: rheumatoid arthritis versus sarcoidosis. Neth J Med (1999) 2.03
The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med (2001) 1.96
Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease. Thorax (1996) 1.94
Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax (2001) 1.94
Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J (1996) 1.91
Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis (1993) 1.87
Body composition and exercise performance in patients with chronic obstructive pulmonary disease. Thorax (1991) 1.79
Factors contributing to alterations in skeletal muscle and plasma amino acid profiles in patients with chronic obstructive pulmonary disease. Am J Clin Nutr (2000) 1.73
Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J (1999) 1.62
Comparison of corridor and treadmill walking in patients with severe chronic obstructive pulmonary disease. Phys Ther (1990) 1.61
Long-term outcome of pulmonary rehabilitation in patients with COPD. Chest (1997) 1.60
Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. Am J Clin Nutr (2000) 1.58
Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol (1995) 1.56
Cytokine-induced activation of nuclear factor-kappa B is inhibited by hydrogen peroxide through oxidative inactivation of IkappaB kinase. J Biol Chem (2001) 1.55
Postoperative pulmonary function abnormalities after coronary artery bypass surgery. Respir Med (1992) 1.53
Dual-energy X-ray absorptiometry in the clinical evaluation of body composition and bone mineral density in patients with chronic obstructive pulmonary disease. Am J Clin Nutr (1998) 1.51
Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) (1999) 1.49
Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (1998) 1.47
Response of Saccharomyces cerevisiae to severe osmotic stress: evidence for a novel activation mechanism of the HOG MAP kinase pathway. Mol Microbiol (2000) 1.45
Evaluation of quality of life in sarcoidosis patients. Respir Med (1998) 1.40
Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med (2000) 1.38
Skeletal muscle weakness is associated with wasting of extremity fat-free mass but not with airflow obstruction in patients with chronic obstructive pulmonary disease. Am J Clin Nutr (2000) 1.38
Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. Eur Respir J (1994) 1.30
Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. Eur Respir J (1997) 1.26
Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med (1995) 1.25
Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord (2001) 1.22
Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1999) 1.22
Resting energy expenditure in patients with chronic obstructive pulmonary disease. Am J Clin Nutr (1991) 1.21
Production of the acute-phase protein lipopolysaccharide-binding protein by respiratory type II epithelial cells: implications for local defense to bacterial endotoxins. Am J Respir Cell Mol Biol (2000) 1.20
Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys (2000) 1.18
Total free living energy expenditure in patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1997) 1.16
Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol (2000) 1.14
Adverse effects of the indoor environment on respiratory health in primary school children. Environ Res (1995) 1.14
Body composition by bioelectrical-impedance analysis compared with deuterium dilution and skinfold anthropometry in patients with chronic obstructive pulmonary disease. Am J Clin Nutr (1991) 1.13
Intratracheal instillation of lipopolysaccharide in mice induces apoptosis in bronchial epithelial cells: no role for tumor necrosis factor-alpha and infiltrating neutrophils. Am J Respir Cell Mol Biol (2001) 1.10
Enteral nutrition in intensive care patients: a practical approach. Working Group on Nutrition and Metabolism, ESICM. European Society of Intensive Care Medicine. Intensive Care Med (1998) 1.09
The use of bioelectrical impedance analysis to predict total body water in patients with cancer cachexia. Am J Clin Nutr (1995) 1.07
Energy balance in chronic obstructive pulmonary disease. Am Rev Respir Dis (1991) 1.06
Different patterns of chronic tissue wasting among patients with chronic obstructive pulmonary disease. Clin Nutr (1999) 1.06
Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 1.04
Prevalence of an elevated resting energy expenditure in patients with chronic obstructive pulmonary disease in relation to body composition and lung function. Eur J Clin Nutr (1998) 1.04
Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J (2007) 1.03
Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. Eur Respir J (1997) 1.01
Interval versus continuous training in patients with severe COPD: a randomized clinical trial. Eur Respir J (1999) 1.01
Exercise-induced lactate increase in relation to muscle substrates in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 1.01
Enhanced levels of whole-body protein turnover in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 1.01
Plasma and muscle amino acid levels in relation to resting energy expenditure and inflammation in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 1.00
Chronic obstructive pulmonary disease: evaluation with spirometrically controlled CT lung densitometry. Radiology (1994) 0.99
Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J Clin Oncol (2001) 0.99
Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 0.99
Massive haemoptysis after radiotherapy in inoperable non-small cell lung carcinoma: is endobronchial brachytherapy really a risk factor? Radiother Oncol (1998) 0.98
Estimation of body composition by bioelectrical impedance in cancer patients. Eur J Clin Nutr (1990) 0.97
Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective? Eur Respir J (2009) 0.97
Resting energy expenditure in patients with non-small cell lung cancer. Cancer (1991) 0.97
Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J (1999) 0.97
Outbreak of severe Pseudomonas aeruginosa respiratory infections due to contaminated nebulizers. J Hosp Infect (1996) 0.97
Clinical presentation of sarcoidosis in The Netherlands an epidemiological study. Neth J Med (1998) 0.95
BAL fluid LDH activity and LDH isoenzyme pattern in lipoid pneumonia caused by an intravenous injection of lamp oil. Eur Respir J (1996) 0.95
Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer (2011) 0.95
Decreased mechanical efficiency in clinically stable patients with COPD. Thorax (1997) 0.94
Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci (Lond) (1997) 0.94
Analysis of the energy balance in lung cancer patients. Cancer Res (1994) 0.94
Diagnostic value of BAL fluid cellular profile and enzymes in infectious pulmonary disorders. Eur Respir J (1999) 0.93
Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J (2001) 0.92
Within-day variation of bioelectrical resistance measurements in patients with chronic obstructive pulmonary disease. Clin Nutr (1990) 0.92
Thoracoscopic pleurodesis in the management of spontaneous pneumothorax. Respiration (1988) 0.92
N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. Eur Respir J (1999) 0.92
Pulmonary hypertension and fenfluramine. Eur Respir J (1990) 0.91